Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for XBiotech

    Client Virtual Booth

    XBIOTECH

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    XBiotech
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    5217 WINNEBAGO LN. AUSTIN, TX 78744
    Telephone
    Telephone
    +1 5123862900
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.xbiotech.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/xbiotech-usa-inc.
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
    XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

    https://www.globenewswire.com//news-release/2024/01/04/2804040/35550/en/XBiotech-to-Begin-Constructing-New-R-D-Facility-on-its-48-acre-Campus.html

    GLOBENEWSWIRE
    04 Jan 2024
    Share Share
    Dr. Alan Kivitz to Chair XBiotech™s Natrunix Program in Rheumatoid Arthritis
    Dr. Alan Kivitz to Chair XBiotech™s Natrunix Program in Rheumatoid Arthritis

    https://www.globenewswire.com//news-release/2023/11/14/2780180/35550/en/Dr-Alan-Kivitz-to-Chair-XBiotech-s-Natrunix-Program-in-Rheumatoid-Arthritis.html

    GLOBENEWSWIRE
    14 Nov 2023
    Share Share
    XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin
    XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin

    https://www.globenewswire.com//news-release/2023/09/26/2749600/35550/en/XBiotech-Announces-Enrollment-Completion-of-Phase-I-Clinical-Trial-for-Hutrukin-a-Novel-Candidate-Therapy-for-Stroke.html

    GLOBENEWSWIRE
    26 Sep 2023
    Share Share
    XBiotech Announces Enrollment Completion of Ph II, Placebo Controlled
    XBiotech Announces Enrollment Completion of Ph II, Placebo Controlled

    https://www.globenewswire.com//news-release/2023/08/30/2734388/35550/en/XBiotech-Announces-Enrollment-Completion-of-Phase-II-Placebo-Controlled-Multicenter-Study-for-Natrunix-in-Pancreatic-Cancer.html

    GLOBENEWSWIRE
    30 Aug 2023
    Share Share
    XBiotech Announces First Patient Begins Novel Natrunix Therapy in PII RA Trial
    XBiotech Announces First Patient Begins Novel Natrunix Therapy in PII RA Trial

    https://www.globenewswire.com/news-release/2023/08/08/2720954/35550/en/XBiotech-Announces-First-Patient-Begins-Novel-Natrunix-Therapy-in-Phase-II-Rheumatoid-Arthritis-RA-Clinical-Trial.html

    GLOBENEWSWIRE
    08 Aug 2023
    Share Share
    XBiotech Commences Tender Offer to Purchase $80,000,000 Worth of Its Shares
    XBiotech Commences Tender Offer to Purchase $80,000,000 Worth of Its Shares

    https://www.globenewswire.com/news-release/2023/05/17/2671068/35550/en/XBiotech-Commences-Tender-Offer-to-Purchase-up-to-80-000-000-Worth-of-Its-Shares.html

    GLOBENEWSWIRE
    17 May 2023
    Share Share
    XBiotech Announces First Patient Enrolled French(INCA) Ph I/II/III Natrunix™
    XBiotech Announces First Patient Enrolled French(INCA) Ph I/II/III Natrunix™

    https://www.globenewswire.com/news-release/2022/10/13/2534194/35550/en/XBiotech-Announces-First-Patient-Enrolled-into-the-French-National-Cancer-Institute-INCA-Sponsored-Phase-I-II-III-Clinical-Study-for-Natrunix-Therapy-for-Colorectal-Cancer.html

    GLOBENEWSWIRE
    13 Oct 2022
    Share Share
    XBiotech Successfully Completes PI portion of Pancreatic Cancer Study
    XBiotech Successfully Completes PI portion of Pancreatic Cancer Study

    https://www.globenewswire.com/news-release/2022/06/20/2465392/35550/en/XBiotech-Announces-Successful-Completion-of-Phase-I-portion-of-Pancreatic-Cancer-Study.html

    GLOBENEWSWIRE
    20 Jun 2022
    Share Share
    Why Are XBiotech Shares Trading Higher Today
    Why Are XBiotech Shares Trading Higher Today

    https://www.benzinga.com/general/biotech/22/04/26877445/why-are-xbiotech-shares-trading-higher-today

    Vandana Singh BENZINGA
    28 Apr 2022
    Share Share
    XBiotech Announces ANSM Approval, INSA funding for PII/III Study for Natrunix
    XBiotech Announces ANSM Approval, INSA funding for PII/III Study for Natrunix

    https://www.globenewswire.com/news-release/2022/04/28/2431533/35550/en/XBiotech-Announces-French-National-Agency-ANSM-Approval-and-National-Cancer-Institute-INSA-funding-to-Support-Phase-I-II-III-Clinical-Study-for-Natrunix-in-Combination-with-Triflur.html

    GLOBENEWSWIRE
    28 Apr 2022
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    polpharma-m-2024-04-15

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search